Novel therapeutic strategy to treat leukemia
The ABC2ALL consortium will develop a novel therapeutic strategy to treat B-cell chronic lymphocytic leukemia (CLL).
The consortium will design, produce and validate a therapeutic bispecific monoclonal antibody (mAb) that simultaneously targets two specific receptors expressed on malignant B-cells. This will provide improved efficacy, specificity, and safety when compared to the current treatment regimens. Upon completion of the project, the product will be ready for further clinical development.
The project was awarded a 2,6 milljon Eurostars grant. The consortium consists of Mabsolys Sas from France, Absolute Antibody Ltd. from the UK, Academisch Medisch Centrum from the Netherlands and Biotechpharma Uab from Lithuania.